URO-3 Triple Stain (CD44 + p53) with CK20, Catalog #: PM370TSAA, Package Type: Bag, which contains components: a) CD44 + p53, Catalog #: PM373DSAA, Package Type: Bottle, and b) CK20, Catalog #: PM062AA, Package Type: Bottle Product Usage: URO-3 Triple Stain (CD44 + p53) with CK20 is a cocktail of mouse monoclonal and rabbit monoclonal antibodies that is intended for laboratory use in the qualitative identification of CD44, p53 and CK20 proteins by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues, primarily for bladder cancer characterization. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient s clinical history and other diagnostic tests by a qualified pathologist. The URO-3 Triple Stain is an adjunct immunohistochemistry test to assist a qualified pathologist in differentiating urothelial reactive atypia from CIS (carcinoma in situ) in suspected bladder lesions. The URO-3 staining pattern will be used as supporting data along with morphological and patient history context for the qualified pathologist to render a diagnosis.
Published September 26, 2018 · Recall initiated: March 15, 2018
Summary
FDA records medical device Class II recall Z-3198-2018, published September 26, 2018 and initiated March 15, 2018. Recalling firm: Biocare Medical, LLC; Status: Terminated; Reported quantity: 11; Lot: Lot: 060617, Expiration: 2019/05 with a) Lot: 060117, and b) 053117. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Immunohistochemistry device kits found to display incorrect staining pattern due to mislabeling of two components.
What to do
Voluntary: Firm initiated · E-Mail
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Biocare Medical, LLC
- Distributor
- Worldwide Distribution - Unites States Nationwide in the states of NY AND FL and the countries of: Morocco and Italy
- Lot
- Lot: 060617, Expiration: 2019/05 with a) Lot: 060117, and b) 053117
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDAintelliPATH Universal HRP Detection Kit, REF: IPK5011G80, containing DAB Buffer, Catalog Number: IPBF5009G20;November 13, 2024
- FDAVITEK(R) 2 AST-P655, For susceptibility testing of Staphylococcus spp. Enterococcus spp., ad S agalactiaeSeptember 26, 2018
- FDADisposable Insulin Syringe 0.3mL in 3 different sizes 29Gx1/2, 30Gx5/16, and 31G x 5/16. (10 syringes areSeptember 26, 2018
- FDAINFORM HPV III Fam 16 Probe - US Export, Catalog Number 05278856001, model 800-4295 Immunohistochemistry (IHC)September 26, 2018
- FDAOptetrak Logic CC Stem Extension, 22mm x 160mm The OPTETRAK Logic CC Total Knee System is indicated for use inSeptember 26, 2018
- FDAVENTANA anti-Helicobacter Pylori (SP48) PAB 250, Catalog Number 06425623001, model 790-1015September 26, 2018
Questions about this recall
Was URO-3 Triple Stain (CD44 + p53) with CK20, Catalog #: PM370TSAA, Package Type: Bag, which contains components: a) CD44 + p53, Catalog #: PM373DSAA, Package Type: Bottle, and b) CK20, Catalog #: PM062AA, Package Type: Bottle Product Usage: URO-3 Triple Stain (CD44 + p53) with CK20 is a cocktail of mouse monoclonal and rabbit monoclonal antibodies that is intended for laboratory use in the qualitative identification of CD44, p53 and CK20 proteins by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues, primarily for bladder cancer characterization. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient s clinical history and other diagnostic tests by a qualified pathologist. The URO-3 Triple Stain is an adjunct immunohistochemistry test to assist a qualified pathologist in differentiating urothelial reactive atypia from CIS (carcinoma in situ) in suspected bladder lesions. The URO-3 staining pattern will be used as supporting data along with morphological and patient history context for the qualified pathologist to render a diagnosis. recalled?
Yes. FDA published recall Z-3198-2018 on September 26, 2018. Reported hazard: Immunohistochemistry device kits found to display incorrect staining pattern due to mislabeling of two components.
What should I do if I have this product?
Voluntary: Firm initiated · E-Mail